Can the positive findings from POD1UM-304 improve patient care worldwide?
Mené sur 583 patients atteints d'un cancer du poumon non à petites cellules de stade métastatique (âge médian : 64 ans), cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout du rétifanlimab à une chimiothérapie de première ligne à base de sels de platine
In the past decade, the treatment landscape for non-oncogene-addicted non-small-cell lung cancer (NSCLC) has changed substantially. Immune checkpoint inhibitors, either alone or combined with chemotherapy (the latter especially in tumours with PD-L1 expression of less than 50%), are recommended by clinical guidelines as first-line treatment regimens.1 These recommendations are supported by multiple phase 3, randomised clinical trials that show both the efficacy and the safety of immune checkpoint inhibitor-based treatment regimens
The Lancet Respiratory Medicine , commentaire, 2025